Market Overview

UPDATE: Bank of America Downgrades Idenix Pharmaceuticals to Neutral on Regulatory Hurdles

Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Bank of America lowered its rating on Idenix Pharmaceuticals (NASDAQ: IDIX) from Buy to Neutral and reduced its price objective from $8 to $6.

Bank of America commented, "We are downgrading IDIX shares from Buy to Neutral based on a series of recent conversations, with mgmt as well as industry & academic experts at recent conferences (ICAAC Sep 9-12, and EASL-AASLD HCV Special Conf Sep 14-16), that left us with limited hope that IDIX will convince the FDA to allow further clinical testing of HCV nuc drug candidates with a ā€œGā€ base."

Idenix Pharmaceuticals closed at $5.64 on Tuesday.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (IDIX)

View Comments and Join the Discussion!